Pharmacoeconomic evaluation of once-daily aminoglycoside treatment.
A special topic in pharmacoeconomics concerns antimicrobial therapy. The cost of antimicrobial therapy and an economic evaluation of aminoglycoside antibiotics in the last 30 years are reviewed. Some innovative approaches have been found to be effective in the control of the use of aminoglycosides and those are: 1) selecting the appropriate aminoglycoside, 2) therapeutic drug monitoring and, 3) once-daily administration. The practical advantages of once-daily aminoglycoside dosing are discussed and the conclusion is that combination therapy continues to be a mainstay in several serious Gram-negative infections. Concerns about breakthrough infection with extended aminoglycoside dosing intervals can be resolved by combination with a betalactam antibiotic. The lower costs associated with once-daily aminoglycoside dosing are the consequence of a straightforward dosage calculation, a guaranteed peak serum concentration in the therapeutic range, potential reduction in treatment period, easier quality control of preparation and administration, decreased personnel time, and fewer assays. However, some practical considerations remain unanswered.
Periti
P
P
Department of Preclinical and Clinical Pharmacology, University of Florence, Italy.
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000191:economics*; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D012141:Respiratory Tract Infections / Q000188:drug therapy
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents